| Previous Close | 0.0210 |
| Open | 0.0242 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0241 - 0.0280 |
| 52 Week Range | 0.0021 - 0.0900 |
| Volume | 12,490 |
| Avg. Volume | 46,409 |
| Market Cap | 6.819M |
| Beta (5Y Monthly) | 3.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0290 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to provide a regulatory update pursuant to the temporary relief granted by regulators due to COVID-19. On June 2, 2020 The Company issued a regulatory update and the delayed filing of the third quarter of fiscal year ending June 30, 2020. On June 11, 2020 the Company issued a news release pleased to announce the successful delivery of CleanCare™ Hand Sanitizers to retail customers in the in the US, including the orders announced in a news release on April 15th of this year.
Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to provide an important clarification about Bioganix CleanCare, its brand of disinfection and wellness products. June 19, 2020, the FDA issued a public health warning about nine (9) hand sanitizers manufactured by Eskbiochem SA, four (4) “CleanCare No Germ Advanced” branded products that could contain potentially dangerous chemicals.
Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the appointment of Mr. James Mansour, an award-winning brand and marketing executive to its advisory board. Mr. James Mansour is an award-winning branding authority who works closely with Global Brands to ensure success. Mr. Mansour was instrumental in the development of many brands that became icons in the marketplace and multi-billion-dollar businesses including Victoria’s Secret, the #1 Lingerie Brand in the world, and Bath and Body Works, the #1 Beauty Products Specialty Retailer in the world.
Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce it has expanded and continues to expand its CleanCare™ product line as it prepares to address increased government and institutional demand for disinfection supplies in preparation for a potential second wave of COVID-19. Defense Ministers from NATO have asked member nations to contribute to an emergency fund to buy even more supplies as the alliance braces for a second wave of the pandemic. Relevium Technologies continues to innovate and bring new products to market to address market demand for critical health and wellness products including surface disinfectants in the form of liquid sprays and wipes, targeting B2B institutional and government customers.
Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the successful delivery of Cleancare™ Hand Sanitizers to retail customers in the in the US, including the orders announced in a news release on April 15th of this year. The Company expects to begin fulfillment for its B2C customers over the next 15 days as it builds inventory levels. On April 2, 2020, Relevium announced that it had sourced and would begin the commercialization of a line of Bioganix Cleancare hand sanitizers, in response to the COVID-19 pandemic.
Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), as a requirement in order to obtain final regulatory approval for its private placement as announced on Monday May 25, 2020, is pleased to provide a full update on the developments and transactions announced over the last 12 months. Relevium, like many other companies related to cannabis, experienced a significant decrease in its market valuation, which was proportional to the average decrease in value of all cannabis companies trading on both the CSE and TSX.
Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), today announced that it will be delaying the filing and delivery of certain of its continuous disclosure documents, in accordance with Decision No 2020-PDG-0023 of the Autorité des marchés financiers (Québec) (the “Exemption”),which was adopted for the purpose of providing certain filing and other relief to issuers in light of the challenges posed by the COVID-19 pandemic. The Company is relying on the Exemption by delaying the filing of its quarterly financial statements and related management discussion and analysis for the period ended March 31, 2020 required pursuant to National Instrument 51-102 Continuous Disclosure Obligations and the filing of the related certifications(collectively, the "Required Filings") and compliance with the delivery requirements of applicable securities laws relating to the Required Filings.
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to announce today a private placement offering of up to 58,000,000 units (the “Units”) of the Company at a price of $0.035 per Unit (the “Offering”), with each Unit consisting of one share and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder to acquire one common share of the Company at a strike price of $0.05 for a period of two years from the date of issuance. The Warrants are subject to an acceleration feature if the volume weighted average price of the common shares trades at or above $0.075 on the TSX Venture Exchange (“TSXV”) for a period of 7 consecutive days starting from four months and a day from closing.
Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce today that its expanding its CleanCare™ hand sanitizing line to include two new retail formats as well as one new institutional format, the later targeting critical needs of retirement homes and community centers across Canada and the US. Relevium, through its integrated supply chain is successfully expanding production capabilities for CleanCare™ hand sanitizers to over 100,000 units per week. Bioganix® CleanCare™ hand sanitizer formulation kills 99.9% of germs and bacteria and is now available in 8 oz, 16 oz and 1-gallon formats.
Relevium Technologies Inc. (TSX.V:“RLV”, OTC:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that the company will be presenting at the Mi3 Investor and Broker Video Conference this Friday April 24th at 12:00PM Eastern Time. Aurelio Useche, CEO will discuss the “new normal” in terms of social interactions, in particular as we prepare to resume economic activities. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce today that its new line of Bioganix® CleanCare hand sanitizers has been met with very strong pre-sales demand of approximately one quarter of a million dollars since the product was made available on April 9, 2020. Last week, on April 9, 2020, the Company announced it had lunched its pre-order platform for its 8oz format of CleanCare of hand sanitizers on a pre-order first-come, first-served basis, making the product available, making the new product available in Canada and US. “We are very please with the initial reception of our Bioganix® CleanCare hand sanitizers, at a time when a new standard for social interactions and personal care is in development,” stated Aurelio Useche, CEO of Relevium.
Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce today it has partnered with Montreal based air purification leaders to launch a new line of residential and office air purification systems. “There is now growing concern that the current and future viral infections could be transmitted via airborne particles and we expect that over the longer-term consumers will become more conscious about in-home prevention” stated Aurelio Useche, CEO of Relevium. The product will be available both, in Canada and in the United States through the Company’s native website www.bioganix.com.
Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that the company has launched its newly launched Bioganix® CleanCare hand sanitizer product on pre-order to consumers in the Canadian market and the US. The Company will begin accepting pre-orders for the company’s new hand sanitizer products and will be shipped out to Canadian customers on a first-come first-served basis.
Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that it has secured the natural product number (“NPN”) for the Canadian market and is ready to launch the product for Canadian customers. Relevium is leveraging product formulation and manufacturing expertise of its integrated supply chain in Montreal to commercialize the newly announced Bioganix® CleanCare hand sanitizers that effectively kills 99.9% of germs and bacteria. The Company, through its local manufacturing partner, has secured Health Canada Natural Product Number (“NPN number”) and will begin accepting pre-sale orders on a first-come, first-served basis.
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce today that a pre-order platform where customers can purchase in advance and reserve its new line of Cleancare hand sanitizers by Bioganix ®. The Company will begin accepting pre-orders for the company’s new Cleancare hand sanitizer products and will be shipped out to customers on a first come first serve basis.
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce today it has sourced and will begin commercializing a line of Bioganix® hand sanitizers. Relevium is leveraging its strong network of suppliers and formulators to manufacture and bring to market a line of hand sanitizers under the Bioganix ® Cleancare. The Company will have an initial format of 8oz (235ml) that will effectively kill 99.9% of germs and bacteria.
Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is announces the passing of Dr. Tina Sampalis, Director and Scientific Officer of the Company. It is with heavy hearts and great sadness that we announce the passing of our colleague and friend Dr. Tina Sampalis MD, PhD. Tina passed peacefully on Sunday, March 1, 2020 after facing cancer with courage, resilience and tenacity.
Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that the Company’s subsidiary, BGX E-Health LLC (“BGX”), has shipped a total of CAD $130,000 worth of generic formulations to its customer, Innova Health Care based in Saudi Arabia. This represents the first shipment of the initial CAD $1,000,000 purchase order the Company received, as mentioned in a press release dated October 30th 2019. CEO of Relevium Mr. Useche stated “This first shipment to our international customer presents a new milestone for the Company as it embarks on expanding with global partners around the world for generic formulations and nutraceuticals.”
Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to report second quarter results for fiscal year ending June 30, 2020. The Company reported increased revenues for the reporting period.
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce a shareholder information video-conference call to provide an update on the current business and ongoing developments disclosed to the market. The CEO video-conference call will take this Friday February 7 at 12:00PM (Montreal or Eastern Time).
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to provide an update on the proposed transaction with Newscope Capital. As announced in a letter from the CEO issued on December 19, 2019, one of the Company’s main focus for 2020 is the crystallization of the value of the existing business units. On October 29, 2019, the Company announced it had executed an LOI with Newscope Capital to unlock the value of its nutraceutical business.
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to provide an open letter to its shareholders from the company’s Chief Executive Officer, Aurelio Useche. As the year comes to a close and we take a look back at the Canadian capital markets in 2019 we see a new valuation model emerging and renewed investor diligence.
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the launch of LeefyLyfeTM Organics, a comprehensive line of organic health and wellness products formulated with broad spectrum organically sourced Scandinavian hemp. The carefully crafted premium line of organic hemp extracts are sourced from slow-grown hemp and extracted with CO2 and formulated with MCT oil and rich flavonoids to enhance overall well-being. The Company has launched a 1000Mg Organic Hemp Oil Drops with Citrus flavonoids and a 1000Mg Organic Hemp Gummy Bears with Wild Berry flavonoids, both part of an initial series of eight (8) products planned to be released over the next six months.
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce it has executed a letter of intent to acquire a Montreal based biopharma contract manufacturing company through its wholly owned subsidiary BGX e-Health LLC. The transaction is subject to customary due diligence and the parties have agreed to keep the vendors information confidential until such a time when the definitive agreement is executed. The target of the transaction is a Montreal based Biopharma company that manufactures for private label, white label and for its own brands of over the counter health products sold in Canada and the US.
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the appointment of Mark Billings, CFA as Chief Financial Officer for both Relevium and Biocannabix Health Corporation effective immediately. Mr. Billings replaces Faycal Salek who has resigned to pursue other opportunities. Mr. Billings is an experienced executive Chartered Financial Analyst and a graduate of the Harvard School of Business.